Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3379MR)

This product GTTS-WQ3379MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets Canlupfam CD52 gene. The antibody can be applied in Canine T-cell lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001003240.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 403918
UniProt ID Q28896
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ3379MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ129MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 11F8
GTTS-WQ13763MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ10354MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY 3090106
GTTS-WQ9027MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ4364MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ15746MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ6977MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ETI-204
GTTS-WQ9907MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA KB-003
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW